Literature DB >> 3360247

Progressive CT appearance of hepatic metastases from colorectal carcinoma.

J G Letourneau1, W M Thompson, M E Goldberg, D C Snover, T B Grage, M P Frick.   

Abstract

An 8-year retrospective review of 106 serial computed tomographic (CT) examinations performed on 32 patients with colorectal carcinoma metastatic to the liver was done to determine if the CT appearance of such metastases changed with a favorable response to chemotherapy or with progression of disease. Of these 32 patients, 15 underwent placement of an infusion pump for delivery of chemotherapy directly into the hepatic artery, 3 underwent partial hepatectomy, 1 underwent both procedures, and 13 underwent neither. Regression of hepatic metastases (7 patients), only seen following infusion pump placement, was associated with a decrease in size and an increase in margination of lesions. In two of these patients regression of metastases was seen in one area of the liver with subsequent progression or development of metastases in another region, presumably due to preferential delivery of chemotherapeutic agent. Progression of disease (23 patients) was associated with an increase in both size and number of lesions that became progressively less well marginated. Development of poorly marginated or infiltrative characteristics at the periphery of the lesion was associated with a poor prognosis. Thus, the CT characteristics of hepatic metastases from colorectal carcinoma differ with a favorable response to chemotherapy and with progression of disease.

Entities:  

Mesh:

Year:  1988        PMID: 3360247     DOI: 10.1007/bf01889044

Source DB:  PubMed          Journal:  Gastrointest Radiol        ISSN: 0364-2356


  20 in total

1.  Preliminary results of a randomized study of intrahepatic infusion versus systemic infusion of 5-fluoro-2'-deoxyuridine for metastatic colorectal carcinoma.

Authors:  N Kemeny; J Daly
Journal:  Recent Results Cancer Res       Date:  1986

2.  Detection of recurrent rectosigmoid carcinoma: prospective evaluation of CT and clinical factors.

Authors:  S M McCarthy; D Barnes; K Deveney; A A Moss; H I Goldberg
Journal:  AJR Am J Roentgenol       Date:  1985-03       Impact factor: 3.959

3.  Hepatic arterial embolization for hepatocellular carcinoma. Comparison of CT scans and resected specimens.

Authors:  K Takayasu; N Moriyama; Y Muramatsu; M Suzuki; T Yamada; K Kishi; H Hasagawa; N Okazaki
Journal:  Radiology       Date:  1984-03       Impact factor: 11.105

4.  Effect of occult hepatic metastases on survival after curative resection for colorectal carcinoma.

Authors:  I G Finlay; C S McArdle
Journal:  Gastroenterology       Date:  1983-09       Impact factor: 22.682

5.  Intra-arterial radionuclide infusion: a new technique to assess chemotherapy perfusion patterns.

Authors:  W D Kaplan; C J D'Orsi; W D Ensminger; E H Smith; D C Levin
Journal:  Cancer Treat Rep       Date:  1978-05

6.  Computed tomography, ultrasound, and scintigraphy of the liver in patients with colon or breast carcinoma: a prospective comparison.

Authors:  P O Alderson; D F Adams; B J McNeil; R Sanders; S S Siegelman; H J Finberg; S J Hessel; H L Abrams
Journal:  Radiology       Date:  1983-10       Impact factor: 11.105

7.  Computed tomography in carcinoma of the rectum.

Authors:  W Zaunbauer; M Haertel; W A Fuchs
Journal:  Gastrointest Radiol       Date:  1981-01-15

8.  Detection and staging of primary rectal and rectosigmoid cancer by computed tomography.

Authors:  R F Thoeni; A A Moss; P Schnyder; A R Margulis
Journal:  Radiology       Date:  1981-10       Impact factor: 11.105

9.  Value of computed tomography in the detection and staging of recurrent rectal carcinomas.

Authors:  A A Moss; R F Thoeni; P Schnyder; A R Margulis
Journal:  J Comput Assist Tomogr       Date:  1981-12       Impact factor: 1.826

10.  Incidence and detection of occult hepatic metastases in colorectal carcinoma.

Authors:  I G Finlay; D R Meek; H W Gray; J G Duncan; C S McArdle
Journal:  Br Med J (Clin Res Ed)       Date:  1982-03-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.